• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

已确诊骨质疏松症患者骨折预防的成本效益

Cost-effectiveness of fracture prevention in established osteoporosis.

作者信息

Jönsson B, Christiansen C, Johnell O, Hedbrandt J

机构信息

Department of Economics, Stockholm School of Economics, Sweden.

出版信息

Osteoporos Int. 1995 Mar;5(2):136-42.

PMID:7599450
Abstract

This study presents the results of a computer simulation model for calculating the cost-effectiveness and cost-utility of treating patients with established osteoporosis in order to reduce the risk of fractures. The results are based on Swedish data for risk of fracture and costs. The treatment intervention modelled is based on treatment of a 62-year-old woman with established osteoporosis. The cost per hip fracture avoided is 350,000 SEK, assuming a 50% reduction in the risk of fracture due to 5 years of treatment. A sensitivity analysis for changes in the cost and effectiveness of treatment, the risk of fracture and the discount rate is performed. The cost per life-year gained and the cost per quality-adjusted life-year (QALY) gained is presented to enable comparison of the cost-effectiveness of treating osteoporosis with that of other health care interventions. A comparison between treating the same woman for osteoporosis and mild hypertension shows a cost per life-year gained of 220,000 SEK and 128,000 SEK respectively. Cost per QALY gained is very similar for the two interventions: 105,000 SEK and 103,000 SEK respectively. This model provides a tool to enable clinicians, administrators and health policy makers to analyze and understand the economic aspects of a major health policy issue.

摘要

本研究展示了一个计算机模拟模型的结果,该模型用于计算治疗已确诊骨质疏松症患者以降低骨折风险的成本效益和成本效用。结果基于瑞典的骨折风险和成本数据。所模拟的治疗干预措施基于对一名62岁已确诊骨质疏松症女性的治疗。假设经过5年治疗骨折风险降低50%,则避免每例髋部骨折的成本为350,000瑞典克朗。对治疗成本和效果、骨折风险以及贴现率的变化进行了敏感性分析。给出了每获得一个生命年的成本以及每获得一个质量调整生命年(QALY)的成本,以便能够将治疗骨质疏松症的成本效益与其他医疗保健干预措施的成本效益进行比较。对同一名女性进行骨质疏松症治疗和轻度高血压治疗的比较显示,每获得一个生命年的成本分别为220,000瑞典克朗和128,000瑞典克朗。两种干预措施每获得一个QALY的成本非常相似,分别为105,000瑞典克朗和103,000瑞典克朗。该模型提供了一种工具,使临床医生、管理人员和卫生政策制定者能够分析和理解一个重大卫生政策问题的经济方面。

相似文献

1
Cost-effectiveness of fracture prevention in established osteoporosis.已确诊骨质疏松症患者骨折预防的成本效益
Osteoporos Int. 1995 Mar;5(2):136-42.
2
Cost-effectiveness of fracture prevention in established osteoporosis.已确诊骨质疏松症患者骨折预防的成本效益
Scand J Rheumatol Suppl. 1996;103:30-8; discussion 39-40.
3
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.三种推荐用于治疗骨质疏松症的药物的卫生经济学比较
Int J Clin Pharmacol Res. 2004;24(1):1-10.
4
Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.男性和女性骨质疏松症的干预阈值:一项基于瑞典数据的研究
Osteoporos Int. 2005 Jan;16(1):6-14. doi: 10.1007/s00198-004-1623-4. Epub 2004 Apr 22.
5
The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.英国社区筛查以减少老年女性骨质疏松性骨折的成本效益:SCOOP 研究的经济评估。
J Bone Miner Res. 2018 May;33(5):845-851. doi: 10.1002/jbmr.3381. Epub 2018 Feb 22.
6
Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.接受芳香化酶抑制剂治疗早期乳腺癌的绝经后妇女骨折预防的成本效益。
J Clin Oncol. 2012 May 1;30(13):1468-75. doi: 10.1200/JCO.2011.38.7001. Epub 2012 Feb 27.
7
Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.瑞典、美国和英国高骨折风险女性激素治疗的成本效益——基于女性健康倡议随机对照试验的结果
Bone. 2008 Feb;42(2):294-306. doi: 10.1016/j.bone.2007.09.059. Epub 2007 Oct 23.
8
Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment.骨折复位影响医疗保险经济学(FRAME):骨质疏松症诊断与治疗增加的影响
Osteoporos Int. 2005 Dec;16(12):1545-57. doi: 10.1007/s00198-005-1869-5. Epub 2005 Jun 8.
9
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.老年男性骨密度测定及随后骨质疏松症治疗的成本效益分析
JAMA. 2007 Aug 8;298(6):629-37. doi: 10.1001/jama.298.6.629.
10
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.阿仑膦酸盐与胆钙化醇固定剂量复方制剂在英国和荷兰治疗及预防骨质疏松症的成本效益分析
Curr Med Res Opin. 2008 Mar;24(3):671-84. doi: 10.1185/030079908X260998. Epub 2008 Jan 24.

引用本文的文献

1
Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.罗莫佐单抗治疗墨西哥骨折极高风险的重度绝经后骨质疏松症的成本效益分析。
PLoS One. 2025 Feb 7;20(2):e0299673. doi: 10.1371/journal.pone.0299673. eCollection 2025.
2
Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.定义识别成人和儿童乳糜泻的最佳策略:系统评价和经济建模。
Health Technol Assess. 2022 Oct;26(44):1-310. doi: 10.3310/ZUCE8371.
3
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.

本文引用的文献

1
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.共识发展会议:骨质疏松症的诊断、预防及治疗
Am J Med. 1993 Jun;94(6):646-50. doi: 10.1016/0002-9343(93)90218-e.
2
Predicting various fragility fractures in women by forearm bone densitometry: a follow-up study.通过前臂骨密度测定法预测女性的各种脆性骨折:一项随访研究。
Calcif Tissue Int. 1993 May;52(5):348-53. doi: 10.1007/BF00310197.
3
Consequences of a hip fracture: a prospective study over 1 year.髋部骨折的后果:一项为期1年的前瞻性研究。
在加拿大,使用罗莫佐单抗治疗绝经后骨折高危女性的成本效益分析。
Arch Osteoporos. 2022 Apr 26;17(1):71. doi: 10.1007/s11657-022-01106-9.
4
[Subtrochanteric femoral fractures].[股骨转子下骨折]
Unfallchirurg. 2013 Dec;116(12):1097-112; quiz 1113-4. doi: 10.1007/s00113-013-2525-8.
5
Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain.在西班牙,巴多昔芬与雷洛昔芬治疗绝经后女性的成本效益比较
Clinicoecon Outcomes Res. 2013 Jul 5;5:327-36. doi: 10.2147/CEOR.S42755. Print 2013.
6
Cost-effectiveness of universal serologic screening to prevent nontraumatic hip and vertebral fractures in patients with celiac disease.对伴有乳糜泻的患者进行普遍血清学筛查以预防非外伤性髋部和脊柱骨折的成本效益分析。
Clin Gastroenterol Hepatol. 2013 Jun;11(6):645-53. doi: 10.1016/j.cgh.2012.12.037. Epub 2013 Jan 26.
7
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.地舒单抗治疗绝经后骨质疏松症的成本效果分析。
Osteoporos Int. 2011 Mar;22(3):967-82. doi: 10.1007/s00198-010-1424-x. Epub 2010 Oct 9.
8
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.利塞膦酸钠在英国使用 FRAX 治疗骨质疏松症的成本效益分析。
Osteoporos Int. 2010 Mar;21(3):495-505. doi: 10.1007/s00198-009-0989-8. Epub 2009 Jun 30.
9
The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.锶雷尼酸酯治疗骨质疏松症的成本效果分析-英国研究
Osteoporos Int. 2010 Feb;21(2):339-49. doi: 10.1007/s00198-009-0971-5. Epub 2009 Jun 10.
10
[Epidemiology and perspectives in traumatology of the elderly].[老年创伤学的流行病学与展望]
Unfallchirurg. 2007 Jun;110(6):553-60; quiz 561-2. doi: 10.1007/s00113-007-1286-7.
Osteoporos Int. 1993 May;3(3):148-53. doi: 10.1007/BF01623276.
4
Mortality and morbidity after hip fractures.髋部骨折后的死亡率和发病率。
BMJ. 1993 Nov 13;307(6914):1248-50. doi: 10.1136/bmj.307.6914.1248.
5
Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered.绝经后雌激素用于预防骨质疏松症。如果考虑心血管方面的影响,获益几乎没有风险。
Am J Med. 1986 Jun;80(6):1115-27. doi: 10.1016/0002-9343(86)90674-1.
6
Costs of hip fracture. Rehabilitation of 180 patients in primary health care.髋部骨折的费用。初级卫生保健机构中180名患者的康复情况。
Acta Orthop Scand. 1991 Feb;62(1):39-48. doi: 10.3109/17453679108993089.
7
The costs of treating hypertension in Sweden. An empirical investigation in primary health care.瑞典高血压治疗的成本。初级卫生保健中的实证研究。
Scand J Prim Health Care. 1991 Sep;9(3):155-60. doi: 10.3109/02813439109018511.
8
Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group.低骨密度老年女性的非创伤性死亡率。骨质疏松性骨折研究组研究。
Lancet. 1991 Aug 10;338(8763):355-8. doi: 10.1016/0140-6736(91)90489-c.
9
Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.影响骨代谢的药物在预防髋部骨折方面疗效的证据。
BMJ. 1992 Nov 7;305(6862):1124-8. doi: 10.1136/bmj.305.6862.1124.
10
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.鼻内给予鲑降钙素对已确诊骨质疏松症患者骨量和骨折发生率的影响:一项剂量反应研究。
BMJ. 1992 Sep 5;305(6853):556-61. doi: 10.1136/bmj.305.6853.556.